{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["aglatimagene besadenovec (CAN-2409)"]],"indication":"localized prostate cancer","name":"NCT01436968","nct_id":"NCT01436968","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct01436968. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"PrTK03","arms":[{"description":"Aglatimagene besadenovec (CAN-2409) + valacyclovir + radiation therapy +/- ADT","label":"ProstAtak®","type":"EXPERIMENTAL"},{"description":"Placebo + valacyclovir + radiation therapy +/- ADT","label":"Control","type":"PLACEBO_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2030-12","type":"ESTIMATED"},"conditions":["Prostate Cancer"],"enrollment":{"count":711,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Aglatimagene besadenovec + valacyclovir","otherNames":["AdV-tk","CAN-2409"],"type":"BIOLOGICAL"},{"name":"Placebo + valacyclovir","otherNames":[],"type":"BIOLOGICAL"}],"last_update":"2026-10-02","lead_sponsor":"Candel Therapeutics, Inc.","official_title":"A Randomized Controlled Trial of ProstAtak® as Adjuvant to Up-front Radiation Therapy For Localized Prostate Cancer","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2024-08","type":"ACTUAL"},"primary_outcomes":[{"measure":"Disease free survival defined as the time from randomization until the date of the first failure event will be compared for the ProstAtak® arm versus the placebo control arm. The analyses will be based on the intent to treat population.","timeFrame":"Assessed at each visit every 6 months through year 5 until event occurs."}],"references":[{"citation":"DeWeese TL, Manzanera A, Sylvester J, Wheeler T, Schroeder T, Gejerman G, Chesnut G, Facelle TM, Garzotto MG, Pieczonka C, Gandhi NM, Sukin S, Liss MA, Tutrone R, Mehlhaff B, Savage SJ, Goody M, Vogt J, Rao S, Polanco MLS, Barone F, Nichols WG, Tak PP; PrTK03 study team. Aglatimagene besadenovec (CAN-2409) with radiotherapy for patients with localised prostate cancer: a phase 3, multicentre, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2026 Jun;27(6):673-685. doi: 10.1016/S1470-2045(26)00071-9.","pmid":"42225101","type":"DERIVED"}],"start_date":{"date":"2011-09"},"study_type":"INTERVENTIONAL","title":"Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer","url":"https://clinicaltrials.gov/study/NCT01436968"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct01436968"}